Open Nav

Orig3n, Inc.

  • Robin Smith, Orig3n, Inc.


  • Date:Thursday, October 18
  • Time:3:15 PM - 3:30 PM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Orig3n exists at the intersection of biology and emerging technology, advancing the future of health through regenerative medicine and genetic testing. Orig3n is pursuing allogeneic, iPSC-derived, cell therapy programs in a variety of indications, including osteoarthritis and cardiovascular. We have build the largest cell bank in the world for commercial cell therapy applications, and have identified cell lines from the bank that are matched to the immune profiles of 90% of the US population. Orig3n also offers the largest suite of direct-to-consumer genetic tests, the revenues from which are directed to supporting its cell therapy programs. The founding team are successful serial entrepreneurs with 60+ years of experience in the life sciences. The founders have 3 prior successful exits - the two most recent were VC-backed and both sold to publicly traded companies. The most recent exit provided a 24:1 return and 74% IRR to investors.
  • Company
  • Company HQ City:Boston, MA
  • Company HQ Country:United States
  • Company HQ State:Massachusetts       
  • CEO/Top Company Official:Robin Y. Smith, President and CEO
  • Year Founded:2014
  • Main Therapeutic Focus:Regenerative Medicine
  • Lead Product in Development :Osteoarthritis, Cardiovascular
  • Development Phase of Primary Product:Pre-Clinical
  • Previous and Current Investors:Hatteras Venture Partners, Haitong Capital, LabCorp, 180 Degree Capital, Mountain Group Capital, KTB
  • Total Amount Raised to Date, In All Rounds:$50 million
Robin Smith
Orig3n, Inc.